Please login to the form below

Not currently logged in
Email:
Password:

SGLT2 inhibitors

This page shows the latest SGLT2 inhibitors news and features for those working in and with pharma, biotech and healthcare.

J&J seeks US OK to add CV claim to Invokana label

J&J seeks US OK to add CV claim to Invokana label

The filing is based on the results of the CANVAS trial, which showed that its SGLT2 inhibitor Invokana (canagliflozin) was able to reduce the combined risk of cardiovascular death, myocardial infarction ... The US regulator's current thinking is that

Latest news

  • Trial of J&J's canagliflozin boosts SGLT2 cardiovascular credentials Trial of J&J's canagliflozin boosts SGLT2 cardiovascular credentials

    Trial of J&J's canagliflozin boosts SGLT2 cardiovascular credentials. Invokana cuts risk of heart failure hospitalisation by a third. ... J's drug, care should be taken when prescribing all drugs in the class as "data available to date are limited and

  • FDA won't add outcomes data to Januvia label FDA won't add outcomes data to Januvia label

    The DPP-4 inhibitors as a class are facing stiffer competition from SGLT2 inhibitors - another class of type 2 diabetes drugs that have data indicating they can actually improve cardiovascular outcomes. ... The EMPA-REG OUTCOME trial showed that Eli

  • AZ data suggest SGLT2 inhibitors can reduce heart failure risk AZ data suggest SGLT2 inhibitors can reduce heart failure risk

    AZ data suggest SGLT2 inhibitors can reduce heart failure risk. Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. ... SGLT2 inhibitors cut hospitalisations for heart failure by 39% and all-cause mortality by 51%

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... SGLT2 inhibitors remove glucose through the urine by blocking blood glucose

  • AstraZeneca's Forxiga set to be recommended by NICE AstraZeneca's Forxiga set to be recommended by NICE

    Currently in the final stages of consultation, the guidance endorses the use of AstraZeneca's SGLT2 inhibitor Forxiga (dapagliflozin) in patients already taking two drugs for blood sugar control without success. ... It has since been backed as a

More from news
Approximately 3 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J& J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. “ ... Forxiga is set to face competition from other SGLT2 inhibitors either recently approved or on the horizon, including

  • Pharma deals during April 2013 Pharma deals during April 2013

    SGLT2 inhibitors block the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels. ... Clearly the pressure is on, the announcement coming only a month after Johnson &Johnson obtained US approval for its

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics